Takeda Pharmaceuticals' dengue vaccine assumes significance since the first vaccine ever licensed for dengue, developed by French drugmaker...

Johnson & Johnson's recent announcement heralds a promising breakthrough in combatting dengue fever, often known as "breakbone fever" due t...

The Dengue Alliance, a coalition of institutions from dengue-endemic countries, plans to develop a new treatment for dengue within five yea...

Vaccine manufacturer Indian Immunologicals Limited (IIL) expects to commercially launch its dengue fever vaccine by early 2026, a top execu...

Gennova had in April submitted interim data on India's first indigenously developed mRNA Covid-19 vaccine to the Central Drug Standard Cont...

India is not a part of the global Phase-3 trial of the Takeda dengue vaccine candidate, which means as per local regulation it will have to...

The indigenous whole virion inactivated SARS-Cov-2 virus vaccine company has also said that Covaxin will even undergo the phase 4 trials to...

Seagull Biosolutions is the first company the government is financially backing for coronavirus vaccine efforts. It will also produce at-ho...

Phase 3 trials are the last phase of clinical trials that a company conducts before it receives approval to market the drug here.

This is the Mumbai-based company’s second collaboration focussed on the mosquito-borne virus, the first being its pact to develop a botanic...

Sun Pharma will fund and support further development of the vaccine candidate and existing ICGEB knowhow and patents.

The ICGEB plans a larger vaccine trial on monkeys in America; the full-fledged human trial after that could cost more than Rs 100 crore.

The decision of the apex committee is expected to delay the entry of the vaccine, which has been approved in Mexico, the Philippines and Br...

Serum Institute will develop a drug to treat all 4 strains of dengue, and is in the process of applying for a 'speedy approval' to roll-out...

While antibody 5J7 has been found to be effective against DENV-3, the remaining two serotypes of dengue virus (DENV-2 and DENV-4) have to b...

Country Head, Sanofi Pasteur, Stephan Barth, said dengue is a serious health concern in India, causing a significant but under-reported bur...

The study showed that 87% of Indian adults in trial were positive to dengue at enrolment, confirming the significant endemic nature of the ...